Document is current

Article History

Received: 14 October 2025

Accepted: 17 February 2026

First Online: 7 March 2026

Declarations

:

: AG is a member of the CDDF board of directors and of the supervisory boards of Ryvu Therapeutics SA and Active Biotech AB; he has received consultancy fees from Active Biotech AB and Oncopeptides AB. BW is an employee of Bayer AG, Berlin Germany. PZ is an employee of Debiopharm International S.A., Lausanne, Switzerland. EC is an employee of Roche Products Limited, UK. BP reports consultancy fees from BMS-Celgene, GSK, Janssen, Roche, Sanofi, and Takeda; research funding from AstraZeneca, Beigene, BMS, GSK, Roche, and Sanofi; honoraria from Adaptive, Amgen, Becton/Dickinson Biosciences, BMS-Celgene, GSK, Janssen, Roche, and Sanofi. CUG reports funding from Astellas, Sanofi, Jansen-Cilag Bayer, Amgen, Merck, Gilead, Novartis, AstraZeneca, Roche, National Institute of Health (NIH), Dutch Health Care Institute (ZIN), Horizon Europe projects ASCERTAIN and DEFINITIVE. All payments to Erasmus University Rotterdam. JV is a consultant to Boehringer Ingelheim, IDRX, and DeuterOncology. KL , LZ , PZ , MM , AS , FS and MLT have nothing to disclose.